Gaps and Disparities in Celiac Disease Screening: A Nationwide Analysis of a High-Risk Pediatric Population

Erin B P Miller1, Kate Avery1, Amy Ratner1

  • 1Beyond Celiac, Ambler, PA, USA.

PubMed

Insights

Celiac disease (CeD) screening adherence is low in children with high-risk conditions, with only 10% screened. Non-White and younger children face significant disparities in CeD screening.

Area of Science:

  • Pediatric gastroenterology
  • Public health screening initiatives
  • Autoimmune disease epidemiology

Background:

  • Celiac disease (CeD) screening guidelines exist for high-risk pediatric populations.
  • Undiagnosed CeD can lead to severe long-term health issues.
  • Current screening adherence among eligible children remains unclear.

Purpose of the Study:

  • To evaluate adherence to celiac disease (CeD) screening guidelines in children with high-risk conditions.
  • To identify disparities in CeD screening based on age, race, and specific conditions.

Main Methods:

  • Retrospective cohort analysis of US private payer claims data (2007-2022).
  • Identified children (≤20 years) with high-risk conditions for CeD screening.
  • Used descriptive statistics, chi-square tests, and logistic regression to analyze screening rates and associated factors.

Main Results:

  • Only 10.0% of 223,449 eligible children were screened for CeD.
  • Children with a family history of CeD had the highest screening rate (55.49%).
  • Non-White children and those under 11 years were screened significantly less than White children and older peers, respectively. These disparities persisted in multivariable analysis.

Conclusions:

  • Significant gaps exist in adhering to CeD screening guidelines for children.
  • Younger and Non-White children experience notable under-screening.
  • Improved awareness and implementation of CeD screening practices are crucial for high-risk pediatric groups.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251